INVITATION:
Stakeholder Engagement Session on Phase II of the Transfer of pCODR to CADTH

December 22, 2014

Hello,

On April 1, 2014, the pan-Canadian Oncology Drug Review (pCODR) was transferred to CADTH to further enhance and consolidate policy direction across drug review processes, and to improve the pCODR governance structure to ensure its long-term viability and sustainability.

During phase I of the transition, we worked to ensure the seamless transfer of pCODR staff, processes, funding, and expertise.

For phase II of the transition, the Conference of Deputy Ministers of Health asked us to explore better alignment of pCODR and the CADTH Common Drug Review evaluation criteria, and build upon the best practices of both review processes.

As part of our commitment to stakeholder engagement, we are inviting representatives from pharmaceutical manufacturers and associations, and consultants, to attend an information and feedback session on:

Thursday, February 5, 2015
2:00 p.m. to 4:00 p.m. EST
Delta Meadowvale Hotel and Conference Centre
6750 Mississauga Road
Mississauga, Ontario, L5N 2L3

A teleconference option will be provided for individuals or organizations unable to join us in person.

The purpose of this information session will be to:

- Provide an update on the work to better align the pCODR and CADTH Common Drug Review processes
- To seek feedback on key areas of phase II of the transition.

The discussion panellists from CADTH will include:

- Dr. Brian O'Rourke, President and Chief Executive Officer, CADTH
- Mr. Scott Livingstone, Chair, pCODR Advisory Committee; and Chief Executive Officer, Saskatchewan Cancer Agency
- Ms. Judy McPhee, Chair, Drug Policy Advisory Committee; and Executive Director, Nova Scotia Department of Health and Wellness
- Dr. Chander Sehgal, Director, CADTH Common Drug Review and Optimal Use
- Dr. Mona Sabharwal, Executive Director, pCODR

The contributions of representatives from pharmaceutical manufacturers and associations, and consultants, have been invaluable in shaping the CADTH Common Drug Review and pCODR processes. We hope you will be able to join us to continue this collaborative effort.

Please RSVP by **January 30, 2015** using our online registration form. Because of the limited number of spaces available, each organization will be allowed a **maximum of three (3) participants** to attend in person. An agenda and teleconference details will be sent to those who cannot join us on-site.